The earnings call reflected strong financial performance and successful product launches, particularly for Jakafi, Opzelura, and Niktimvo. However, increased R&D expenses and a delay in the regulatory timeline for V617F Phase I data were noted as challenges.

Company Guidance

During Incyte's Q2 2025 earnings call, the company provided updated guidance for its financial performance and strategic priorities. Total product revenues reached $1.06 billion, a 17% increase year-over-year, driven by strong demand for Jakafi and Opzelura, alongside the successful launch of Niktimvo. Jakafi alone contributed $764 million, marking an 8% year-over-year growth. As a result of this performance, Incyte raised its full-year revenue guidance for Jakafi to $3 billion to $3.05 billion. The company also increased its guidance for other oncology products to $500 million to $520 million, reflecting the strong launch of Niktimvo and increased demand for Zynyz. Incyte is strategically focusing on driving product flow and growth, especially in hematology-oncology and immunology markets. The company aims to advance its pipeline with urgency, particularly the promising mutant-CALR monoclonal antibody, INCA033989, and povorcitinib, with several pivotal trials and potential FDA approvals anticipated in the near term.

Strong Financial Performance

Incyte delivered strong financial results with total product revenues of $1.06 billion, representing an increase of 17% year-over-year. Total revenues were $1.22 billion, up 16% versus the same period last year.

Jakafi Revenue Growth

Jakafi net product revenue was $764 million for the second quarter, representing an 8% growth year-over-year. As a result of the strong demand seen in the first half of the year, full year revenue guidance for Jakafi has been raised to a new range of $3 billion to $3.05 billion.

Opzelura Performance

Opzelura total net product revenue for the second quarter was $164 million, representing a 35% increase year-over-year. U.S. net product revenue of $132 million was up 19% year-over-year.

Niktimvo Launch Success

Niktimvo net product revenues in the second quarter were $36 million. The product has achieved roughly 82% account penetration with rapid and broad uptake in BMT centers across the U.S.

R&D Progress

Incyte made excellent progress in R&D, with expectations for FDA approval for Opzelura in pediatric patients and pivotal trials for povorcitinib on track. The company is also advancing INCA033989 development with promising data in essential thrombocytemia.

Incyte (INCY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INCY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	1.58 / -	1.07	―	―	―
Jul 29, 2025	2025 (Q2)	1.40 / 1.57	-1.818	186.47% (+3.39)
Apr 29, 2025	2025 (Q1)	0.98 / 1.16	0.643	80.40% (+0.52)
Feb 10, 2025	2024 (Q4)	1.50 / 1.43	1.058	34.78% (+0.37)
Oct 29, 2024	2024 (Q3)	1.05 / 1.07	1.1	-2.73% (-0.03)
Jul 30, 2024	2024 (Q2)	0.75 / -1.82	0.9	-302.00% (-2.72)
Apr 30, 2024	2024 (Q1)	0.78 / 0.64	0.1	543.00% (+0.54)
Feb 13, 2024	2023 (Q4)	1.15 / 1.06	0.13	713.85% (+0.93)
Oct 31, 2023	2023 (Q3)	0.83 / 1.10	0.5	120.00% (+0.60)
Aug 01, 2023	2023 (Q2)	0.70 / 0.90	0.72	25.00% (+0.18)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INCY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$70.16	$77.38	+10.29%
Apr 29, 2025	$59.52	$60.43	+1.53%
Feb 10, 2025	$74.13	$68.30	-7.86%
Oct 29, 2024	$65.69	$73.60	+12.04%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Incyte Corp (INCY) report earnings?

Incyte Corp (INCY) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Incyte Corp (INCY) earnings time?

Incyte Corp (INCY) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INCY EPS forecast?

INCY EPS forecast for the fiscal quarter 2025 (Q3) is 1.58.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing